CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
CancerVax, Inc. announced that its experimental therapy successfully activated human antiviral Killer T-cells in in-vitro studies. The platform uses 'Smart mRNA' to disguise cancer cells as viral infections, triggering the body's immune system to attack them.
Why it matters
This represents a potential breakthrough in immunotherapy, offering a novel approach to treating cancer by leveraging existing human immune responses.
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells
Lehi Utah, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CancerVax, Inc. , the developer of a breakthrough universal cancer treatment platform that "tricks” the body’s immune system into fighting cancer, today announced that it has successfully activated human antiviral memory CD8+ T-cells. Before T-cells can kill cancer cells, they must be first activated. The latest studies validated this important part of the platform.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in